Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclosporin A protects lung function from hyperoxic damage.

E Matthew1, R Pun, M Simonich

  • 1Department of Molecular and Cellular Physiology, University of Cincinnati Medical Center, Cincinnati, Ohio 45267-0576, USA.

The American Journal of Physiology
|May 18, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.

ESMO open·2022
Same author

Effect of Dupilumab in a Patient With Severe Asthma Complicated With Recurrent Anaphylaxis: A Case Report.

Journal of investigational allergology & clinical immunology·2022
Same author

Growth Characteristics of Female Radiation/Clinical Oncologists in South Asia: Assessment of Gender Neutrality and Leadership Position.

Clinical oncology (Royal College of Radiologists (Great Britain))·2022
Same author

Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib.

ESMO open·2021
Same author

Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma.

ESMO open·2021
Same author

Visualization and quantification of anastomotic perfusion in colorectal surgery using near-infrared fluorescence.

Techniques in coloproctology·2019
Same journal

Blood coagulation in fish.

The American journal of physiology·2011
Same journal

Renal tubular reabsorption, metabolic utilization and isomeric fractionation of lactic acid in the dog.

The American journal of physiology·2010
Same journal

The inactivation of placental toxin by human serum.

The American journal of physiology·2010
Same journal

Adrenal function following ovariectomy in the rat.

The American journal of physiology·2010
Same journal

Capillary permeability; perfusion of frog and guinea pig hind limbs.

The American journal of physiology·2010
Same journal

Evaluation of protective measures against sunburn.

The American journal of physiology·2010
See all related articles

Cyclosporin A (CsA) protects lungs from hyperoxia-induced injury by improving lung compliance and reducing immune cell infiltration. This suggests CsA may benefit patients requiring prolonged high-oxygen therapy.

Area of Science:

  • Pulmonary Medicine
  • Immunology
  • Cell Biology

Background:

  • Hyperoxia (>95% oxygen) causes lung injury, surfactant deficiency, and immune responses.
  • Cyclosporin A (CsA), a calcineurin inhibitor, influences exocytosis and neutrophil mobility.

Purpose of the Study:

  • To investigate the effects of CsA on lung alveolar type II cells and its protective potential against hyperoxia-induced lung injury in mice.

Main Methods:

  • Examined CsA's effect on ATP-stimulated exocytosis in lung alveolar type II cells.
  • Administered CsA to mice before or during 72 hours of hyperoxia exposure.
  • Assessed lung compliance, neutrophil infiltration, edema, and histological changes.

Main Results:

  • CsA enhanced exocytosis in alveolar type II cells.

Related Experiment Videos

  • CsA attenuated hyperoxia-induced reductions in lung compliance.
  • CsA reduced neutrophil infiltration, capillary congestion, edema, and hyaline membrane formation.

    • Conclusions:

    • CsA demonstrates protective effects against hyperoxia-induced lung injury in mice.
    • CsA may be a potential therapeutic agent for patients undergoing prolonged high-oxygen therapy or experiencing other lung injuries.